PRVA News and Press, Privia Health Group Inc. From 03/25/22

Privia Health Group, Inc. (PRVA) Q4 2021 Earnings Conference Call March 23 2022, 08:30 AM ET Company Participants Robert Borchert - SVP, Investor and Corporate Communications Shawn Morris - CEO David Mountcastle - CFO Parth Mehrotra - President and COO Conference Call Participants Josh Raskin...

The following slide deck was published by Privia Health Group, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Privia Health Group, Inc. 2021 Q4 - Results - Earnings Call Presentation

Image source: The Motley Fool. Privia Health Group, Inc. (NASDAQ: PRVA) Q4 2021 Earnings Call Mar 23, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Privia Health Group, Inc. (PRVA) Q4 2021 Earnings Call Transcript...

Privia Health Group press release (NASDAQ:PRVA): Q4 GAAP EPS of -$0.11 beats by $0.02. Revenue of $275.33M (+28.8% Y/Y) beats by $48.83M. For further details see: Privia Health Group GAAP EPS of -$0.11 beats by $0.02, revenue of $275.33M beats by $48.83M

Jeff Sherman, Executive Vice President and Chief Financial Officer (CFO) of Privia Health (NASDAQ:PRVA), has resigned from the positions to pursue other opportunities. Mr. Sherman joined the company on Jan. 5, 2022. Subsequently, Privia Health reappointed David Mountcastle as CFO. Mr. Mountca...

FY 2021 Financial Results Above High End of Guidance FY 2022 Guidance Highlights Practice Collections Growth of 30.7% at Midpoint Entries into California, Montana and West Texas help to Accelerate 2022 Growth Launches Three New ACOs; Four Existing ACOs particip...

Gainers: HOOKIPA Pharma HOOK +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen OCGN +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines FIXX -27%. Karyopharm The...

ARLINGTON, Va., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) announced that the Company’s management team will participate in a virtual fireside chat as part of the SVB Leerink 11 th Annual Global Healthcare Conference on Wednesday, February 16, 2022...

Privia Health Group (PRVA +1.8%) has partnered with Javara to advance a phase 2/3 study for mRNA-1345, an investigational vaccine candidate developed by Moderna (NASDAQ:MRNA) for the respiratory syncytial virus (RSV). Operating as an Integrated Research Organization, Javara delivers access to...

Javara Contributes to RSV Prevention Vaccine Trial in Collaboration with Privia Health and Moderna Adults Age 60 and Older in Georgia, Maryland and Texas Encouraged to Join Clinical Trial for RSV Prevention Vaccine PR Newswire WINSTON-SALEM, N.C. , Feb. 14, 202...